Empagliflozin for kidney health in African American veterans
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is testing whether the drug empagliflozin (Jardiance) can help protect the kidneys of African American veterans who already have some kidney damage but do not have diabetes. The goal is to see if the drug can reduce damage at the cellular level.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an African American veteran.
- You are 18 years or older.
- You have some kidney damage but not severe (eGFR between 20 and 89, and if your eGFR is 60-89, you must have some protein in your urine).
- Your blood pressure is controlled (140/90 or lower).
- You do not have diabetes.
- Your body mass index (BMI) is between 18 and 39.9.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This study tests whether finerenone, a medication that protects the kidneys and heart, can help African American veterans with type 2 diabetes and early kidney damage. If you qualify, you may receive the study drug and close monitoring of your kidney function and blood sugar.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This study tests a pill called empagliflozin (commonly used for diabetes) to see if it can help people with chronic kidney disease who do not have diabetes. It looks at whether the drug can protect your blood vessels and slow down how quickly your kidneys get worse.
Hear when a new Chronic Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.